These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37132470)

  • 21. Unmet clinical needs and burden of disease in hidradenitis suppurativa: real-world experience from EU5 and US.
    Ingram JR; Bettoli V; Espy JI; Kokolakis G; Martorell A; Villani AP; Wallinger H; Coak E; Kasparek T; Muscianisi E; Richardson C; Kimball AB
    J Eur Acad Dermatol Venereol; 2022 Sep; 36(9):1597-1605. PubMed ID: 35445469
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interventions for hidradenitis suppurativa.
    Ingram JR; Woo PN; Chua SL; Ormerod AD; Desai N; Kai AC; Hood K; Burton T; Kerdel F; Garner SE; Piguet V
    Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD010081. PubMed ID: 26443004
    [TBL] [Abstract][Full Text] [Related]  

  • 23. External Validation of the IHS4-55 in a European Antibiotic-Treated Hidradenitis Suppurativa Cohort.
    van Straalen KR; Tzellos T; Alavi A; Benhadou F; Cuenca-Barrales C; Daxhelet M; Daoud M; Efthymiou O; Giamarellos-Bourboulis EJ; Guillem P; Gulliver W; Jemec GBE; Katoulis A; Koenig A; Lazaridou E; Lowes MA; Marzano AV; Matusiak L; Molina-Leyva A; Moltrasio C; Pinter A; Potenza C; Prens EP; Romaní J; Saunte DM; Sayed C; Skroza N; Stergianou D; Szepietowski JC; Trigoni A; Vilarrasa E; Kyrgidis A; Zouboulis CC; van der Zee HH
    Dermatology; 2023; 239(3):362-367. PubMed ID: 36630943
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation of the refined Hurley classification for hidradenitis suppurativa with patient-reported quality of life and objective disease severity assessment.
    Rondags A; van Straalen KR; van Hasselt JR; Janse IC; Ardon CB; Vossen ARJV; Prens EP; van der Zee HH; Horváth B
    Br J Dermatol; 2019 May; 180(5):1214-1220. PubMed ID: 30512186
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adalimumab Dose Intensification in Recalcitrant Hidradenitis Suppurativa/Acne Inversa.
    Zouboulis CC; Hansen H; Caposiena Caro RD; Damiani G; Delorme I; Pascual JC; Reguiai Z; Trigoni A; Vilarrasa E; Alfageme Roldán F
    Dermatology; 2020; 236(1):25-30. PubMed ID: 31630144
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quality of life measurement in hidradenitis suppurativa: position statement of the European Academy of Dermatology and Venereology task forces on Quality of Life and Patient-Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa.
    Chernyshov PV; Zouboulis CC; Tomas-Aragones L; Jemec GB; Svensson A; Manolache L; Tzellos T; Sampogna F; Pustisek N; van der Zee HH; Marron SE; Spillekom-van Koulil S; Bewley A; Linder D; Abeni D; Szepietowski JC; Augustin M; Finlay AY
    J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):1633-1643. PubMed ID: 31037773
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation between Depression, Quality of Life and Clinical Severity in Patients with Hidradenitis Suppurativa.
    Sampogna F; Fania L; Mastroeni S; Fusari R; Napolitano M; Ciccone D; Mazzanti C; Pallotta S; Panebianco A; Abeni D
    Acta Derm Venereol; 2020 Nov; 100(18):adv00319. PubMed ID: 32985674
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: A post hoc analysis of PIONEER 1 and 2 individual patient data.
    Frew JW; Jiang CS; Singh N; Grand D; Navrazhina K; Vaughan R; Krueger JG
    J Am Acad Dermatol; 2020 May; 82(5):1150-1157. PubMed ID: 31881294
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development and validation of IHS4-55, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativa.
    Tzellos T; van Straalen KR; Kyrgidis A; Alavi A; Goldfarb N; Gulliver W; Jemec GBE; Lowes MA; Marzano AV; Prens EP; Sayed CJ; van der Zee HH; Zouboulis CC
    J Eur Acad Dermatol Venereol; 2023 Feb; 37(2):395-401. PubMed ID: 36184889
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lymecycline vs. clindamycin plus rifampicin in hidradenitis suppurativa treatment: clinical and ultrasonography evaluation.
    Caposiena Caro RD; Molinelli E; Brisigotti V; Offidani A; Bianchi L
    Clin Exp Dermatol; 2021 Jan; 46(1):96-102. PubMed ID: 32683727
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.
    Kimball AB; Jemec GB; Yang M; Kageleiry A; Signorovitch JE; Okun MM; Gu Y; Wang K; Mulani P; Sundaram M
    Br J Dermatol; 2014 Dec; 171(6):1434-42. PubMed ID: 25040429
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: An open-label cohort study.
    Frew JW; Navrazhina K; Grand D; Sullivan-Whalen M; Gilleaudeau P; Garcet S; Ungar J; Krueger JG
    J Am Acad Dermatol; 2020 Nov; 83(5):1341-1348. PubMed ID: 32416208
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patient-reported outcomes in hidradenitis suppurativa.
    Vellaichamy G; Braunberger TL; Jones JL; Peacock A; Nahhas AF; Hamzavi IH
    G Ital Dermatol Venereol; 2019 Apr; 154(2):137-147. PubMed ID: 30375207
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A cross-sectional study of pediatric hidradenitis suppurativa and the value of the International Hidradenitis Suppurativa Severity Score System (IHS4) as a pediatric clinical trial inclusion criteria.
    Bui H; Sayed C
    Pediatr Dermatol; 2022 Sep; 39(5):689-694. PubMed ID: 35766518
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Validation of the Hidradenitis Suppurativa Investigator Global Assessment: A Novel Hidradenitis Suppurativa-Specific Investigator Global Assessment for Use in Interventional Trials.
    Garg A; Zema C; Ciaravino V; Rolleri R; Peterson L; Garcia L; Massaro T; Jemec GBE; Kirby JS; Thorlacius L; Ingram JR
    JAMA Dermatol; 2023 Jun; 159(6):606-612. PubMed ID: 37099284
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proof-of-concept study exploring the effect of spesolimab in patients with moderate-to-severe hidradenitis suppurativa: A randomized, double-blind, placebo-controlled clinical trial.
    Alavi A; Prens E; Kimball AB; Frew JW; Krueger JG; Mukhopadhyay S; Gao H; Ranganathan U; Ivanoff NB; Hernandez Daly AC; Zouboulis CC
    Br J Dermatol; 2024 Apr; ():. PubMed ID: 38576350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa.
    Gulliver W; Zouboulis CC; Prens E; Jemec GB; Tzellos T
    Rev Endocr Metab Disord; 2016 Sep; 17(3):343-351. PubMed ID: 26831295
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-World Moderate-to-Severe Hidradenitis Suppurativa: Decrease in Disease Burden With Adalimumab.
    Gulliver W; Alavi A; Wiseman MC; Gooderham MJ; Rao J; Shayesteh Alam M; Papp KA; Desjardins O; Jean C
    J Cutan Med Surg; 2022; 26(4):361-370. PubMed ID: 35322692
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Personal Impact of Daily Wound Care for Hidradenitis Suppurativa.
    Moloney S; McGrath BM; Roshan D; Gethin G
    Dermatology; 2022; 238(4):762-771. PubMed ID: 34929704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.